BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Schulte N, Li M, Zhan T, Dreikhausen L, Sollors J, Antoni C, Diehl S, Schoenberg SO, Rahbari N, Reissfelder C, Giordano FA, Ebert MP, Teufel A. Response of advanced HCC to pembrolizumab and lenvatinib combination therapy despite monotherapy failure. Z Gastroenterol 2020;58:773-7. [PMID: 32785913 DOI: 10.1055/a-1190-5681] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 Liu G, Zhou W, Li X, Guo L, He T, Zhao J, Gong L. Case Report: Complete Response of Primary Massive Hepatocellular Carcinoma to Anti-Programmed Death Ligand-1 Antibody Following Progression on Anti-Programmed Death-1 Antibody. Front Immunol 2021;12:712351. [PMID: 34504494 DOI: 10.3389/fimmu.2021.712351] [Reference Citation Analysis]
2 Chan LL, Chan SL. Novel Perspectives in Immune Checkpoint Inhibitors and the Management of Non-Alcoholic Steatohepatitis-Related Hepatocellular Carcinoma. Cancers (Basel) 2022;14:1526. [PMID: 35326677 DOI: 10.3390/cancers14061526] [Reference Citation Analysis]
3 Ziogas IA, Evangeliou AP, Giannis D, Hayat MH, Mylonas KS, Tohme S, Geller DA, Elias N, Goyal L, Tsoulfas G. The Role of Immunotherapy in Hepatocellular Carcinoma: A Systematic Review and Pooled Analysis of 2,402 Patients. Oncologist 2021;26:e1036-49. [PMID: 33314549 DOI: 10.1002/onco.13638] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
4 Lyu N, Yi JZ, Zhao M. Immunotherapy in older patients with hepatocellular carcinoma. Eur J Cancer 2021;162:76-98. [PMID: 34954439 DOI: 10.1016/j.ejca.2021.11.024] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Zhao L, Chang N, Shi L, Li F, Meng F, Xie X, Xu Z, Wang F. Lenvatinib plus sintilimab versus lenvatinib monotherapy as first-line treatment for advanced HBV-related hepatocellular carcinoma: A retrospective, real-world study. Heliyon 2022;8:e09538. [PMID: 35706954 DOI: 10.1016/j.heliyon.2022.e09538] [Reference Citation Analysis]